<DOC>
	<DOCNO>NCT01995617</DOCNO>
	<brief_summary>GEN-004 combination 3 conserve protein Streptococcus pneumoniae . This randomized , double-blind , placebo-controlled , dose escalation study . Eligible subject ( male non-pregnant female ) assign sequentially 1 3 dose cohort randomize 3:1:1 ratio receive GEN-004 adjuvant , GEN-004 without adjuvant , placebo , respectively . Each subject receive 3 dos 4 week interval . Subjects follow safety , tolerability , immunogenicity 12 month last dose .</brief_summary>
	<brief_title>Safety Immunogenicity Study Prophylactic Streptococcus Pneumoniae Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Males nonpregnant female , age 18 55 year inclusive . 2 . Willing able provide write informed consent . 3 . Willing perform comply study procedure include attend clinic visit schedule . 4 . Willing practice adequate contraception may include , limited , abstinence , monogamous relationship vasectomize partner , vasectomy , barrier method condom , diaphragm , intrauterine device , license hormonal method 28 day 90 day receive Study Drug . 1 . Immunocompromised individual , include receive immunosuppressive dos corticosteroid ( 20 mg prednisone give daily alternative day 2 week within 6 month prior first dose Study Drug , dose corticosteroid within 30 day first dose Study Drug , high dose inhale corticosteroid [ &gt; 960 µg/day beclomethasone dipropionate equivalent ] ) immunosuppressive agent . 2 . Presence history autoimmune disease , regardless current treatment . 3 . Insulin dependent diabetes . 4 . Positive serologic test HIV1 hepatitis C infection ; positive hepatitis B surface antigen ( HBsAg ) . 5 . Screening serum chemistry hematology abnormality ≥ Grade 1 . 6 . Screening urinalysis abnormality ≥ Grade 2 . 7 . Positive urine drug screen alcohol Breathalyzer test Screening Study Day 1 . 8 . Other active , uncontrolled comorbidities , opinion Investigator would make subject unsuitable study unable comply study requirement . NOTE : Subjects take medication control underlie comorbidity may enrol change medication within 60 day prior first dose Study Drug . 9 . Any acute illness include , fever ( &gt; 100.4 degree F [ &gt; 38 degree C ] ) within 3 day prior first dose Study Drug . 10 . Pregnant nursing woman . 11 . Receipt investigational drug within 30 day prior first dose Study Drug . 12 . Receipt blood product within 90 day prior first dose Study Drug . 13 . Donation blood plasma within 56 day prior Screening . 14 . Receipt live vaccine within 28 day prior subunit vaccine within 14 day prior first dose Study Drug plan vaccination within 30 day follow last dose Study Drug . 15 . Prior vaccination pneumococcal vaccine . 16 . History hypersensitivity component vaccine history allergic reaction immunization . 17 . History invasive pneumococcal disease ( i.e. , sepsis , meningitis pneumonia bacteremia ) . 18 . History drug alcohol abuse , opinion Investigator , would interfere subject 's ability comply study requirement . 19 . Any condition , opinion Investigator would make subject unsuitable study unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>vaccine</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Strep pneumo</keyword>
</DOC>